Last reviewed · How we verify

Intrathecal morphine administration

University Hospital Ostrava · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Intrathecal morphine administration is a Small molecule drug developed by University Hospital Ostrava. It is currently FDA-approved.

Intrathecal morphine administration is used to treat postoperative pain, particularly after procedures such as hysterectomy. This method involves delivering morphine directly into the spinal canal to provide localized pain relief.

At a glance

Generic nameIntrathecal morphine administration
SponsorUniversity Hospital Ostrava
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intrathecal morphine administration

What is Intrathecal morphine administration?

Intrathecal morphine administration is a Small molecule drug developed by University Hospital Ostrava.

Who makes Intrathecal morphine administration?

Intrathecal morphine administration is developed and marketed by University Hospital Ostrava (see full University Hospital Ostrava pipeline at /company/university-hospital-ostrava).

What development phase is Intrathecal morphine administration in?

Intrathecal morphine administration is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing